Table 2 Group usage and SHM rates in IGHV genes.

From: Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

IGHV group

Expected frequency

Observed frequency

Median SHM % (95% CI)

IGHV1

10 (18.2%)

55 (15.2%)

10.0 (8.6–10.5)

IGHV2

3 (5.4%)

31 (8.6%)

6.5 (6.0–8.0)

IGHV3

26 (47.3%)

191 (52.7%)

8.8 (8.7–9.7)

IGHV4

12 (21.8%)

67 (18.5%)

9.2 (9.2–11.4)

IGHV5

2 (3.6%)

18 (5.0%)

7.2 (6.1–9.0)

IGHV6

1 (1.8%)

0

–

IGHV7

1 (1.8%)

0

–

Total

55

362

8.8 (8.8–9.6)

Comparison of SHM %

Adjusted p value

IGHV1 vs. IGHV2

0.006

  

IGHV2 vs. IGHV4

0.001

  

IGHV2 vs. IGHV3

0.012

  

IGHV1 vs. IGHV5

0.301

  

IGHV4 vs. IGHV5

0.118

  

IGHV3 vs. IGHV5

0.790

  

IGHV1 vs. IGHV4

1

  

IGHV2 vs. IGHV5

1

  

IGHV3 vs. IGHV4

1

  

IGHV1 vs. IGHV3

1

  
  1. The first two columns show the expected IGHV gene usage if all genes were randomly selected compared with the observed frequency within our cohort, respectively. Observed and expected IGHV distributions were not different when the χ2 test was applied, demonstrating that there is no evidence of selection of specific gene groups in myeloma. Median somatic hypermutation rates per IGHV group are shown on the right side of the table. Below, Kruskal−Wallis-based paired comparisons are listed to determine potential differences in the hypermutation rate; a significantly lower mutation rate was found for patients using IGHV2 compared to those using IGHV1 (p = 0.006), IGHV3 (p = 0.012) and IGHV4 (p = 0.001).
  2. 95% CI 95% confidence intervals.
Back to article page